NFC Cunico 20203 NFC Pain MX in Emergency Room

pharmaceuticals
Review
Pain Management in Children Admitted to the Emergency
Room: A Narrative Review
Daniela Cunico 1 , Arianna Rossi 1 , Matteo Verdesca 1 , Nicola Principi 2 and Susanna Esposito 1, *
1 Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy;
dani.cunico@gmail.com (D.C.); arianna.rossi@unipr.it (A.R.); matteo.verdesca@unipr.it (M.V.)
2 Università degli Studi di Milano, 20122 Milan, Italy; nicola.principi@unimi.it
* Correspondence: susannamariaroberta.esposito@unipr.it
Abstract: Pain is a biopsychosocial experience characterized by sensory, physiological, cognitive,

affective, and behavioral components. Both acute and chronic pain can have short and long-term
negative effects. Unfortunately, pain treatment is often inadequate. Guidelines and recommendations
for a rational approach to pediatric pain frequently differ, and this may be one of the most important
reasons for the poor attention frequently paid to pain treatment in children. This narrative review
discusses the present knowledge in this regard. A literature review conducted on papers produced
over the last 8 years showed that although in recent years, compared to the past, much progress has
been made in the treatment of pain in the context of the pediatric emergency room, there is still a lot
to do. There is a need to create guidelines that outline standardized and easy-to-follow pathways for
pain recognition and management, which are also flexible enough to take into account differences in
different contexts both in terms of drug availability and education of staff as well as of the different
complexities of patients. It is essential to guarantee an approach to pain that is as uniform as possible
among the pediatric population that limits, as much as possible, the inequalities related to ethnicity
and language barriers.
Keywords: ibuprofen; NSAID; opioids; pain; paracetamol
Citation: Cunico, D.; Rossi, A.;

Verdesca, M.; Principi, N.; Esposito, S.
Pain Management in Children
1. Introduction
Admitted to the Emergency Room: A According to the International Association for the Study of Pain (IASP), pain is defined
Narrative Review. Pharmaceuticals as an aversive sensory and emotional experience typically caused by, or resembling that
2023, 16, 1178. https://doi.org/ caused by, actual or potential tissue injury [1]. Pain may be acute or chronic. Acute pain
10.3390/ph16081178 is generally associated with the development of a disease, i.e., the exacerbation of an
Academic Editor: Chakradhara Rao already known disease or the implementation of invasive medical procedures. Chronic
Satyanarayana Uppugunduri pain includes recurrent and persistent pain. Recurrent pain is a pain that occurs at least
three times throughout a period of 3 months, whereas persistent pain is a pain that last
Received: 30 June 2023 more than 3 months [2]. In children, pain, both acute and chronic, is very common. A school
Revised: 11 August 2023
survey using a structured self-report questionnaire has shown that 60% of children and
Accepted: 16 August 2023
adolescents reported pain within the previous 3 months and that 21% suffered from chronic
Published: 18 August 2023
pain [3]. Moreover, a cross-sectional observational study of 26,180 patients aged from 2 to
19 years seen in primary care clinics has shown that pain was reported by the patient or
caregivers in 14.9% of visits [4]. The most common causes of acute pain in children are sore
Copyright: © 2023 by the authors.
throat (72%), respiratory tract infections (71%), stomachache (64%), pain associated with
Licensee MDPI, Basel, Switzerland. immunization (59%), headaches (54%), earache (54%), toothache (53%), muscle ache (47%),
This article is an open access article tension headache (39%), and postsurgical pain (39%) [5]. Children suffering from sickle cell
distributed under the terms and disease, hemophilia, juvenile idiopathic arthritis, inflammatory bowel disease, hereditary
conditions of the Creative Commons angioedema, cancer, Mediterranean fever, Fabry’s disease, and Gaucher’s disease are those
Attribution (CC BY) license (https:// at increased risk of chronic pain [6].
creativecommons.org/licenses/by/ Pain is a biopsychosocial experience characterized by sensory, physiological, cognitive,
4.0/). affective, and behavioral components [1]. Acute pain can have both short and long-term
Pharmaceuticals 2023, 16, 1178. https://doi.org/10.3390/ph16081178 https://www.mdpi.com/journal/pharmaceuticals

Pharmaceuticals 2023, 16, 1178 2 of 18
negative effects. Acute consequences include an increase in the child distress and the
development of anxiety and fear as well as a heightening of the pain experience leading to
hyperalgesia. The long-term effects of acute pain are the risk of the development of chronic
pain when nerve stimulation precipitates a series of altered pain pathways, resulting in
central sensitization and impaired central nervous system mechanisms [7,8]. Chronic pain
can significantly weaken the physical and psychological integrity of the patient and his
family. Sleep, cognitive process, brain function, mental health, and cardiovascular health
can be impaired with a significant reduction in quality of life [9–11]. Optimal pain treatment
is of extreme importance to avoid these risks.
Unfortunately, pain treatment is often inadequate. Many children do not receive
pain-relieving therapy in the emergency room. Moreover, despite the fact that it is well
known that timely administration of adequate analgesic therapy positively influences the
outcomes of the underlying condition and affects satisfaction of the child and his/her
parents, antalgics are frequently given much later than needed [12,13]. Protocols for pain
treatment specifically prepared for children may significantly reduce these limitations.
Several national and international scientific institutions have prepared guidelines for a
rational approach to pediatric pain [14–18]. However, the recommendations frequently
differ, and this may be one of the most important reasons for the poor attention frequently
paid to pain treatment in children. This narrative review discusses the present knowledge
in this regard. We conducted a search of PubMed using these words combined with the
use of Boolean operators: “pain management” OR “management of pain” AND “children”.
The search was limited to published articles written in the last 8 years (from 05/2015 to
05/2023) and regarding pediatric age (0–18 years). Then, all the identified studies were
evaluated by title or abstract, and very specific articles, concerning categories of patients
affected by chronic pathologies were excluded. A small amount of information that was
considered important was taken from sources not included in the selection.
2. Assessment of Pediatric Pain

A comprehensive pain assessment is essential to guide clinical pain management. To
face this problem, various rating scales for pediatric pain assessment have been prepared [1].
For preverbal and non-verbal children of any age who are unable to speak or cannot use
appropriate words to express their discomfort adequately, behavioral signs and physiolog-
ical changes are utilized to define the presence and severity of pain [19–23]. Behavioral
measures that can suggest pain include facial expression, excessive crying and irritability,
poor feeding, sleep disturbance, and movement of arms and legs. Evidence of an increase
in heart rate, respiratory rates, and blood pressure and a reduction in oxygen saturation
can favor a more reliable pain assessment [19–23]. All the scales specifically prepared for
neonates, younger infants, or children with cognitive problems include the assessment of
several of the previously reported variables. Based on the presence and intensity of each of
them, a score is created that expresses the severity of the pain. However, the results should
always be interpreted with caution as behavioral measures can reflect fear and anxiety
rather than pain, and physiological measures may depend on stress reactions not correlated
with pain [24]. Moreover, most of the more than 50 scales prepared for the assessment of
pain in neonates and younger children have not been adequately validated. Those more
largely used and that seem to allow the acquisition of reliable data are the Neonatal Infant
Pain Scale (NIPS) [25], the Face, Legs, Activity, Cry, Consolability (FLACC) scale [26], the
EValuation ENfant DOuLeur (EVENDOL) scale [27], the COMFORT scale [28], and the
Neonatal Facial Coding System (NFCS) [29] scale. However, in most cases, validation has
only been obtained for specific subjects and should be used only in these patients. For
example, the FLACC scale has been prepared for evaluating post-operative pain in children
aged from 2 months to 7 years old, whereas the EVENDOL scale has been developed for
children aged from 0 to 7 years old in the emergency department and validated for use in
prehospital settings. Observational scores can be also used to assess pain in toddlers and
older children. In this regard, in addition to EVENDOL [27], reliable data can be collected
with a modified version of the Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS)
that has been validated for evaluating immunization-related pain in children aged from 2
to 22 months old [30].
As pain is a subjective experience, in children with age and neurological development
sufficient to reliably report all the information regarding the severity of the condition
they are experiencing, pain should be evaluated through self-reporting rather than by
proxy [31–33]. In children between 3 and 8 years of age, pain is quantified using pho-
tographs or drawings of faces showing an increase in distress or pain. The child is asked
to choose the face that best describes his pain and record the appropriate number, from 0
to 10, that quantifies the severity. An example in this regard is given by the Wong–Baker
scale [31]. From the age of 8 years, when children can understand the concept of order and
number, verbal scales, numerical scales, and graphic scales, as well as the visual analogue
scale, can be used. Among the scales more frequently used are the NRS-11 scale and the
Color Analog Scale (CAS). The NRS-11 scale is administered verbally. The child is asked
how much pain she or he has by using a number from 0 to 10, where 0 is no pain and
10 is the most or worst pain [32]. The CAS is a plastic instrument with a wedge-shaped
color-gradated figure on one side, a numerical scale on the other, and a moveable slider.
The child must move the slider to the place that shows how much pain he has [33].
The assessment of chronic pain can be significantly more difficult due to the need
to evaluate not only the pain but also all the potential social, emotional, cognitive, envi-
ronmental, and behavioral factors that regularly accompany chronic pain [34]. The Bath
Adolescent Pain Questionnaire (BAPQ) [35], the Patient-Reported Outcome Measurement
Information System (PROMIS) [36], the Pediatric Pain Interference Scale (PPIS) [37], and
the Pediatric Pain Questionnaire (PPQ) [38] are the most common tools used in this regard.
3. Treatment of Pediatric Pain

Generally, scales used to quantify pain severity indicate that scores ≤ 3 correspond
to mild, scores of 4–6 to moderate, and scores ≥ 7 to severe pain [39–42]. In children
with acute pain, mild cases should be approached with non-pharmacologic therapeutic
strategies eventually associated with topical medications and/or non-opioid drugs such as
paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs). Children with moderate
pain should receive the same treatment, although the introduction of weak oral or intranasal
opioids or other analgesics should be considered [39]. In cases with severe pain, strong
opioids intranasal or intravenous (IV) drugs are mandatory, but non opioid analgesics
should be added because of their opioid-sparing effects [40–42]. In children with chronic
pain, together with analgesics, psychological, physical, and occupational measures are
important in order to reduce the limitations due to the underlying disease that cause pain
and improve quality of life [39].
3.1. Non-Pharmacological Approach

Non-pharmacological strategies based on physical and psychological measures to-
gether with distracting activities can be useful, and they can eventually be used in associa-
tion with topical or systemic pharmacological treatment to reduce pain regardless of its
origin [39,43,44]. They are mainly used to reduce pain and anxiety that develop because
of several routinary procedures, such as heel lancing, venipuncture, lumbar puncture, or
intravenous cannulation. Psychological measures include allowing parental presence, pro-
viding reassurance, and maintaining a calm environment. Physical comfort measures based
on oral stimulation with breastfeeding and pacifiers, physical contact based on skin-to-skin
contact, rocking, and swaddling, are appropriate for neonates and younger infants. All the
clinical manifestations of pain typically found in these subjects such as crying and increases
in heart rate, respiratory rate, blood pressure, and muscle tone are significantly reduced
when physical measures are used [43,44].
Preschool children and school-aged children and adolescents can benefit from the
simultaneous use of physical measures and distracting activities. In these patients, cold or
heat packs may be applied to the painful area [45,46]. Cold acts like a mild local anesthetic
and can reduce swelling if applied to an acute injury. Moreover, cold packs can be associated
with a vibration device in order to provide a mild noxious stimulus at one site to inhibit the
pain response at a more distal site. The vibration can block the afferent pain-receptive fibers
by non-noxious fibers, further blocking pain transmission [47]. Heat increases blood flow
and is helpful for relieving generalized aches and stiffness. Interestingly, a recent systematic
literature review investigated the effects of infant massaging on the following outcomes:
pain relief, jaundice, and weight gain [48]. Although the results must be interpreted with
caution, it was shown that infant massaging may be effective at relieving pain, improving
jaundice, and increasing weight gain. Even if statistically significant differences were
not found between all the experimental and control groups, no adverse effects of infant
massaging were observed [48]. Given the dearth of research on infant massaging in the
context of child health care, further research is warranted.
Distracting activities should be chosen considering the age of the patient and can be
based on blowing bubbles, lighted wands, sound, and music for preschool children and
books, movies, and interactive games, such as video or computer games, for the oldest.
Although with differences, all these measures have been found to be effective in reduc-
ing pain, particularly during needle procedures and laceration repair procedures [49–52].
For elective needle procedures, such as blood draws, intravenous access, injections, or
vaccination, overwhelming evidence now mandates that a bundle of four modalities to
eliminate or decrease pain should be offered to every child every time: (1) topical anesthesia,
e.g., lidocaine 4% cream, (2) comfort positioning, e.g., skin-to-skin contact for infants and
not restraining children, (3) sucrose or breastfeeding for infants, and (4) age-appropriate
distraction. A deferral process may include nitrous gas analgesia and sedation [53].
For chronic pain, an interdisciplinary rehabilitative approach, including physical
therapy, psychological treatment, integrative mind–body techniques, and normalizing life,
has been shown to be most effective [53].
Finally, because of the positive effects obtained in adults, a mind–body approach to
pediatric pain management has been suggested [54]. Mindfulness, hypnosis, acupuncture,
and yoga are four examples of mind–body techniques that have been proposed to reduce
opioid use and improve pediatric pain management [55].
Failure to implement evidence-based non-pharmacological pain prevention and treat-
ment for children in medical facilities is now considered inadmissible and a poor standard
of care.
3.2. Pharmacological Approach

3.2.1. Topical Medications
Topical anesthetics should be considered for children who are likely to require any
non-emergent procedure, such as venipuncture, small abscess drainage, lumbar puncture,
or wound closure [56]. For better results, it should be always considered that topical
medications reduce or eliminate pain but have no effect on fear and anxiety. For this they
should be always associated with non-pharmacological measures. There are several topical
anesthetics that when applied on the skin can cause a reversible block in conduction along
the nerve fibers for a few hours post application [57]. Examples in this regard include: (a) a
eutectic mixture of local anesthetic (EMLA) cream (lidocaine 2.5% and prilocaine 2.5%),
which is effective at numbing the tissue below intact skin to a depth of 6–7 mm if left on
for 30–60 min, (b) LMX4, a topical liposomal 4% lidocaine cream similar to EMLA that has
full effectiveness by 30 min, and (c) LET or LAT (lidocaine, epinephrine/adrenaline, and
tetracaine) that works within 20–30 min when applied to open wounds [56].
3.2.2. Paracetamol
Paracetamol (PC) (also known as acetaminophen or N-acetyl-p-aminophenol) is a very
old drug.
It was introduced into clinical practice more than 100 years ago [58]. Despite this, it
remains the first-line treatment of fever and mild-to-moderate acute pain in patients of any
age, including younger infants. It is the only recommended analgesic drug recommended
in infants younger than 3 months of age [58]. The very good tolerability of the drug,
particularly the lack of severe adverse events, is the main reason for PC’s continued success.
The recommended doses for paracetamol vary from 10 to 15 mg/kg every 4–6 h (up to
60 mg/kg/day) [59]. The pharmacokinetic characteristics of PC vary according to age and
body weight. However, the available data seem to indicate that a weight-based dosing
should assure an acceptable efficacy and safety in all children.
For years, it was thought that the analgesic effect of PC depended exclusively on the
inhibition of cyclooxygenase (COX) enzymes and the resulting reduction in prostaglandin
(PG) synthesis [60,61]. On the contrary, recent research has shown that the analgesic activity
of PC is mainly dependent on N-(4-hydroxyphenyl)-arachidonamide (AM404) [62]. This is
formed in the central nervous system (CNS) from the liver metabolite of PC, p-aminophenol,
under the action of the fatty acid amide hydrolase (FAAH) enzyme [63]. AM404 activates
the endocannabinoid system and the transient receptor potential vanilloid-1 (TRPV-1)
channel, thus modulating pain signaling [64]. Additionally, it has been suggested that
PC influences voltage-gated Kv7 potassium channels and inhibits T-type Cav3.2 calcium
channels, thus contributing to a reduction in pain.
The analgesic effect of PC has been repeatedly demonstrated in several studies. Among
them, of interest include those that were carried out in children with dental or tooth-
extraction-related pain [65–68], in those with migraine [69], in those with pharyngotonsilli-
tis [70], and in those with postoperative tonsillectomy pain [71–73]. In all these instances,
the analgesic effect of PC was significantly greater than that of a placebo and noninferior to
that of NSAIDs, including ibuprofen and ketoprofen [74]. Moreover, clinical studies have
shown that using PC, even at low analgesic doses, allows for a significant reduction in the
simultaneous administration of other non-opioid or opioid drugs, thus reducing the risk of
drug-related adverse events [75].
As already highlighted, at therapeutic doses, PC is generally safe and well-tolerated
with an incidence of adverse events that is not substantially different from that of ibuprofen
(odds ratio (OR), 0.82; 95% confidence interval (CI), 0.60–1.12) [74,76]. Nausea, sleepiness,
and constipation were the most common, occurring in about 10% of cases, especially in
children receiving several doses [77]. The only severe adverse event, generally associated
with the prolonged use of higher-than-recommended doses, is severe hepatoxicity that may
lead to death or liver transplantation [74]. This depends on the production of a PC metabo-
lite, N-acetyl-p-benzoquinoneimine, that causes hepatocellular damage. About 90% of
administered PC is metabolized by glucuronidation and sulfation and 10% by cytochrome
P450 (CYP450) with the formation of the toxic metabolite. Severe liver damage has been
documented after the administration of single doses ranging from 120 to 150 mg/kg [78]
or when sustained dosing (>1 day) with >90 mg/kg/day are given [79]. Little importance
is, on the contrary, presently ascribed to the risk of interactions between PC and other
drugs (i.e., rifampicin, phenytoin, carbamazepine, and phenobarbitone), which are metabo-
lized in the liver and that can cause, by the induction or suppression of CYP450 activity,
modifications to plasma PC concentrations, analgesic effects, and the risk of liver damage.
No serious adverse drug interactions with therapeutic doses of paracetamol have been
confirmed in humans.
3.2.3. Non-Steroidal Anti-Inflammatory Drugs

Among this large group of drugs that include both selective and non-selective non-
steroidal anti-inflammatory drugs (NSAIDs), ibuprofen (IB) is the most used to treat pain
in children [74].
IB is a non-selective drug used to treat mild-to-moderate pain alone or in association
with other analgesic measures. IB’s activity is due to the inhibition of both COX-1 and
COX-2 enzymes that results in a strong interference with the conversion of arachidonic acid
into prostaglandins. Prostaglandin inhibition leads to a strong reduction in inflammation

and associated features with a further reduction in pain [80]. Unfortunately, these advan-
tages are associated with the loss of the protective effects exerted by prostaglandins on the
gastric mucosa, the kidney, and the cardiovascular system [81]. Adverse events such as
renal failure, gastric ulcer, intestinal problems, congestive heart failure, hypertension, and
thrombocytopenia have been described after IB administration as well as with all the other
NSAIDs. Fortunately, severe adverse events occur almost only when IB is administered
with doses significantly higher than those capable of significantly reducing pain. With the
recommended dosage, only children with dehydration or those at risk of dehydration and
those with varicella, pneumonia, Kawasaki’s disease, and coagulation disorders have been
found, although rarely, to be at an increased risk of IB toxicity [82]. The age limits for IB use
vary considerably from country to country. The British National Formulary for Children
recommends IB from age 1 month. In contrast, in the USA, IB is only recommended for
children aged at least 6 months [83]. The World Health Organization has authorized IB
from the third month of life. However, similar weight-based doses are recommended.
In children <40 kg, the dose is 5–10 mg/kg every 6 h with a maximum daily dosage of
30–40 mg/kg. Generally, a lower dose is given to infants, although these subjects could
receive a higher dose, as the clearance of the drug is 98% of adult levels by 3 months of
age [84]. In children >40 kg, 200–400 mg every 8 h with a maximum of 1600 mg/day
are recommended [85–88]. The development of IB toxicity is uncommon for doses less
than 100 mg/kg ingested over the total course of treatment. Only doses of 400 mg/kg are
associated with life-threatening clinical manifestations [89,90].
Several studies carried out more than 20 years ago have reported that, at recommended
doses, the analgesic activity of IB is comparable to that of paracetamol [91]. More recent
evaluations, enrolling 535 participants, have indicated that for continuous pain outcomes,
IB is associated with less pain from 4 to 24 h from the treatment onset (standardized mean
difference (SMD), 0.20; 95% CI, 0.03–0.37; p = 0.02) [92]. Moreover, in children with extremity
fractures, IB was found to be as effective as morphine but was tolerated significantly better.
Pain scores at 30 min after administration were significantly and similarly improved
by both analgesics, but the incidence of adverse events was lower in patients receiving
IB [93]. Finally, the use of IB was found to produce an opioid-sparing effect. When given
preoperatively, an IV dose of IB of 10 mg/kg was associated with significantly fewer
doses and amounts of rescue analgesia with opioids [94]. In clinical practice, IB safety and
tolerability was found to be very good and substantially not different from that of PC. The
serious adverse event profile was found to be not substantially different (OR, 1.08; 95% CI,
0.87–1.33; p = 0.50). The coadministration of IB and PC were presumed to be superior to
either agent alone, but no conclusive studies in this regard are available [95]. Finally, the
risk of interactions between IB and other drugs is very low. The most frequently reported
problem in this regard is kidney damage when IB is used alongside with nephrotoxic drugs
such as aminoglycoside antibiotics or diuretics [92–94]. However, at therapeutic doses, no
increased risk of renal failure in children has been reported [92–94].
Due to their strong anti-COX activity and the supposed risk of severe adverse event
risk development, other NAIDs are not recommended to treat pain in children. Despite this,
several studies regarding the use of naproxen, ketoprofen, ketorolac, and diclofenac, mainly
in a perioperative setting, have been carried out. The results were generally good, showing
a potential opioid-sparing effect with no severe adverse events [96,97]. Interestingly, in one
study, adult patients undergoing laparoscopic cholecystectomy were randomly allocated
to one of three groups on admission, depending on a prescribed post-operative analgesic
regimen [98]. The patients allocated to group A received a combination of IV acetaminophen
and intramuscular (IM) pethidine, the patients in group B received a combination of IV
acetaminophen and IV parecoxib, and the patients in group C received IV acetaminophen
monotherapy. Analgesic therapy was administered at regular intervals. Pain was evaluated
utilizing the numeric rating scale (NRS) at five time points. The analgesic regimens of
groups A and B (combination regimens consisting of IV acetaminophen and intramuscular
pethidine and IV acetaminophen and IV parecoxib, respectively) were found to be of

an equivalent efficacy (p = 1.000). In contrast, the patients in group C (acetaminophen
monotherapy) had higher NRS scores compared to the patients in both groups A (p < 0.01)
and B (p < 0.01). Although no data are available in children, this study confirms the notion
of a significant opioid-sparing effect of parecoxib in postoperative pain management after
laparoscopic cholecystectomy [98].
3.2.4. Opioids
Opioids are a group of drugs that have several effects, including deep analgesia [99].
Naturally occurring, synthetic, or semi-synthetic opioids have been identified, depending
on how they are derived. They produce effects on neurons by acting on receptors located
on the membranes of neuronal cells that exist at specific sites in the central and peripheral
nervous systems. Three major types of opioid receptors, mu (µ), delta (δ), and kappa (κ),
have been identified. Although with differences, all three receptors produce analgesia
when an opioid binds to them [96]. Receptor agonists produce analgesia by indirectly
stimulating descending inhibitory pathways with the effect of an activation of descending
inhibitory neurons [100].
Opioids are classified based on the characteristics of how they bind to opioid recep-
tors [101]. Those that strongly bond to receptors, primarily mu (µ) receptors, in the brain
and spinal cord are defined as strong agonists. They are mainly used to treat severe pain.
Examples include morphine, fentanyl, meperidine, and methadone. Mild-to-moderate
agonists are, on the contrary, those opioids that bind to receptors to a lesser degree than
strong agonists and are used to treat moderate pain. Among them are codeine, tramadol,
hydrocodone, and oxycodone [101]. Constipation, drowsiness, itchiness, nausea, and vom-
iting are common opioid-associated adverse events, especially when they are chronically
administered. Some children may require additional medications to help control these
side effects if they become intolerable. In some cases, opioids can also alter a child’s mood
by making them feel euphoric or teary. However, the most important clinical problems,
generally when high doses are used, are hypotension and respiratory depression that can
be severe enough to cause death. For this reason, children receiving opioids, especially
strong agonists given IV for post-surgery analgesia, must be carefully monitored, and a
dose of naloxone, a very strong opioid antagonist, must be always available in order to
quickly reverse the effects of the opioids [102]. In the following sections, details of the most
commonly used opioids for the treatment of pediatric pain are reported.
Morphine
Morphine remains the most used opioid in children with acute severe pain and in
children with postoperative pain. When administered in proper doses, it can significantly
reduce the pain score and the consumption of rescue analgesics with an efficacy not
substantially different or even greater than that of codeine, fentanyl, bupivacaine, or
ketorolac [103–105]. Moreover, although several studies have shown that morphine has a
side effect profile quite similar to that of most opioids, this drug is perceived by most parents
and several health care providers as being potentially more at risk of severe adverse events
than other opioids. This explains why, for several years, morphine has been substituted by
other opioids, mainly codeine, for the treatment of severe pain in children [106]. Only in
recent years, when the risk of poor efficacy or severe adverse effects from codeine use was
clearly evidenced, morphine administration for pain treatment has increased [105].
Codeine
Codeine (CD) is a pro-drug. It is relatively ineffective as an analgesic and can become
effective only when it is metabolized to morphine by the cytochrome P450 isoenzyme
CYP2D6 [107].
Polymorphisms occurring in CYP2D6 can significantly influence CD metabolism
and morphine formation. Four different categories of phenotypes have been described:
ultra-rapid metabolizers, extensive metabolizers, intermediate metabolizers, and poor

metabolizers. Individuals classified as poor metabolizers have a poor analgesic effect
from standard CD doses. On the contrary, ultra-rapid metabolizers that can develop up
to 45-fold higher concentrations of morphine have a very relevant analgesic effect from
CD administration but are at a very high risk of developing all the severe adverse events
commonly ascribed to opioids [108,109]. Whereas poor metabolizers are about 5–10% of
the population [110], ultra-rapid metabolizers are found in about 3–10% in Europe [111]
and between 10% and 30% in Arabian and northeast African countries [112]. Moreover,
the final effect of codeine administration can be further influenced by additional polymor-
phisms affecting morphine metabolism, blood–brain barrier transition, or opioid and opiate
receptor kinetics [107–109]. Lacking genetic studies, the metabolism and analgesic effect
of codeine as well as the risk of adverse events remain unpredictable. On the other hand,
genotyping of the CYP2D6 enzyme is not routinely conducted in the clinical setting as it
is expensive and not widely available outside of research facilities. This means that the
results of CD administration remain totally unpredictable.
CD, alone or in combination with PC or IB, has been used to treat pain in children
for many years because it is available in both liquid and tablet forms, it is relatively
inexpensive, and it is initially considered safe, well-tolerated, and generally effective,
although with differences between children with similar clinical conditions. [113]. In recent
years, however, the knowledge that the final effects of CD could significantly vary, the
availability of alternative drugs with similar analgesic effects, and the reports of several
cases of respiratory depression and death in children that had received standard doses of
codeine have led several scientific institutions worldwide to contraindicate the use of CD
in children [114].
Tramadol
Tramadol is a weak opioid that has replaced CD in the management protocols of pedi-
atric pain since this drug stopped being recommended by the EMA [115] and FDA [116].
However, with time, recommendations for the use of this drug in children have
significantly varied. In Europe, tramadol is approved for the treatment of moderate-to-
severe pain in children over 1–3 years of age, depending on the country, with restrictions
for children after tonsillectomy or adenoidectomy and in those with significant respiratory
problems [117]. In the USA, where the off-label use of the drug remains significant [118], it
is officially not recommended to use tramadol in children <12 years old and in adolescents
<18 years old after ear, nose, and throat surgery. Moreover, it is suggested to pay attention
to the use of tramadol in subjects between 12 and 18 years who are obese or have conditions
that may increase the risk of serious breathing problems [119].
Restrictions to tramadol use are strictly dependent on the potential development
of severe adverse events following drug administration. Similar to codeine, tramadol
is primarily metabolized by CYP2D6 [117–119]. This means that in CYP2D6 ultrarapid
metabolizers, therapeutic doses of tramadol may lead to very high concentrations of O-
desmethyltramadol, the main active metabolite of tramadol. A very relevant alteration to
the release of nociceptive neurotransmitters occurs, and this is followed by the develop-
ment of all the adverse events associated with a massive opioid administration. Sedation,
nausea, vomiting, dizziness, and constipation have been frequently described in children
receiving tramadol. Moreover, severe respiratory compromise leading to death has been
reported, although rarely [120]. Tramadol is also metabolized by CYP3A4 and CYP2B6
with the formation of N-desmethyltramadol. This leads to the inhibition of the reuptake
of the neurotransmitter and further potentiates the analgesic effect. However, in poor
CYP2D6 metabolizers, most of the administered tramadol is metabolized through the sec-
ond pathway, and serotonin syndrome can occur [121]. The analgesic activity of tramadol
has been largely documented in adults with acute or chronic pain that had received the
drug through IV, IM, subcutaneous, oral, and sublingual routes [122]. Studies in children
have generally been carried out in the management of acute pain or in a perioperative
setting. Data regarding its chronic administration are lacking [123]. The results of the
available studies have shown that single or repeated (every 6–8 h) 1–3 mg/kg (maximum
400 mg daily) IV, oral, or sublingual doses are generally effective in reducing or suppressing
severe pain. Moreover, its topic administration has been found to be effective in controlling
postoperative pain in children after tonsillectomy [124–126]. More details about tramadol’s
efficacy were obtained by pooling the results of 20 randomized controlled trials involving
1170 patients who had received the drug for postoperative pain treatment [127]. In this
meta-analysis, it was shown that children receiving tramadol needed less rescue analgesia
in the postoperative care unit than those given a placebo (relative risk (RR), 0.40; 95% CI,
0.20–0.78). On the contrary, the potential superiority of tramadol over other opioids, includ-
ing morphine, remains uncertain. Finally, as adverse events were not adequately monitored
in most of the studies, the risk related to tramadol administration could not be calculated.
In conclusion, several aspects of tramadol use in children need further investigations, and
this may explain why American health authorities do not currently recommend its use in
younger children.
Fentanyl
Fentanyl (FE) is a synthetic opioid that is 75–200 times more potent than morphine,
although it is generally better-tolerated [128].
It has less hypotensive effects and is safer in patients with hyperactive airway disease
because its use is not associated with significant histamine release. FE is available in
several formulations with different strengths. In children, the most common route of
administration is the intranasal route. Transdermal and IV FE are occasionally used in
the treatment of chronic pain and very severe acute pain, respectively. An intranasal FE
dose of 1.5 µg/kg (maximum 100 µg), using the standard fentanyl solution of 50 µg/mL, is
generally sufficient to face mild-to-severe acute pain in children >1 year [128]. This allows
for achieving therapeutic levels within 2 min of administration with a duration of action of
about 30–60 min. A second dose can be given after 5–10 min if required.
The efficacy of intranasal FE has been demonstrated in several studies enrolling
children with burns dressings, acute long bone fractures, abdominal pain, and postoperative
analgesia [129–131]. When compared to other pain treatments, intranasal FE was found to
be at least equally effective. In studies in which intranasal FE was compared to morphine,
it was shown that intranasal FE was as effective as IV morphine and induced a more rapid
reduction in pain than IM morphine. Generally, standard doses of intranasal FE were found
to be safe and well-tolerated. Transient hypoxia was reported in 13% of patients, transient
hypotension in 8% of patients, and drowsiness in 42% of patients [132].
Transdermal FE patches can be used to treat severe long-term pain in children from
2 years of age who have chronic pain, those who have already been receiving at least 30 mg
of oral morphine equivalents per day, and those who have developed a tolerance to other
opioids. The lowest-strength patch capable of reducing pain should be initially used, and
the patch should be replaced every 3 days [133]. However, because a wide range of plasma
concentrations have been observed after its transdermal administration, the dose should be
re-assessed regularly during treatment, and the lowest effective dose should be used. A
blood concentration of 0.6 ng/mL to 3.0 ng/mL is appropriate for analgesia. The risk of
severe adverse events in monitored patients is low, although nausea (10–90%), vomiting
(10–90%), and constipation (50%) are frequently described [134].
IV FE administration by slow IV push (over 1.2 min) can be used to treat very severe
pain [129–131]. In children <6 years, IV FE is given at 0.3–1.5 µg/kg/dose. In children aged
≥6 years, it is administered at 1–5 µg/kg/dose. Further doses can be given every 1–2 h.
Monitoring of respiratory conditions is mandatory, and naloxone must be always available
if severe respiratory depression occurs.
As FE is hepatically metabolized via the CYP450 enzyme system, specifically CYP3A4,
it should not be used concomitantly with drugs such as macrolide antibiotics or azole-
antifungal agents that inhibit these enzymes. In this case, a significant increase in FE
concentrations with an increased risk of opioid-related severe adverse events, including

respiratory depression, can occur [135,136]. Attention should also be paid to patients that
receive CYP3A4 inducers, such as carbamazepine. In this case, the analgesic effect of FE
can be significantly reduced [137].
3.3. Other Analgesic Agents

3.3.1. Nitrous Oxide
Nitrous oxide (NO) is an odorless and colorless gas that has been used for years for
general anesthesia with other anesthetic agents [138]. It also possesses analgesic properties,
acting as a partial agonist at the opioid receptors. NO is given by inhalation through
demand systems in older children or by flow-through systems in younger children. It is
mixed with O2 (30–50%) to avoid hypoxemia, and it is given for 15–30 min. The analgesic
effect is reached within 2–5 min and persists for the same amount of time. NO is used
for the short-term treatment of mild-to-moderate pain or as a bridge to the IV administra-
tion of more effective anesthetics. A systematic review of 30 clinical trials performed in
children [138] showed that: (1) NO was more effective than subcutaneous lidocaine and
oral midazolam and as effective as IV ketamine for pain during laceration repair; (2) the
efficacy of NO for pain during fracture reduction was quite similar to that of IM meperi-
dine plus promethazine, regional anesthesia, and IV ketamine plus midazolam; (3) NO
was more effective than O2 for pain during lumbar puncture; (4) NO was comparable to
oral midazolam for pain during urethral catheterization; and (5) a treatment of NO plus
local anesthetics was more effective than NO or local anesthetics alone for pain during
intramuscular injection.
Despite being generally well-tolerated and safe, NO inhalation can be accompanied by
lightheadedness, headache, dizziness, confusion, nausea, and vomiting as well as euphoria
(laughing gas) [139–141]. NO is contraindicated in cases of pneumothorax, middle ear
obstruction, intestinal obstruction, or recent eye surgery because it causes the expansion of
gas-filled structures when inhaled. NO is also contraindicated in patients with intracranial
hypertension or patients with head trauma because it results in an increase in cerebral
blood flow, further increasing intracranial pressure [139–141].
3.3.2. Ketamine
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that is mainly used
as an anesthetic. At a dose of 1.0 to 1.5 mg/kg IV or 3 to 4 mg/kg IM, ketamine induces the
so-called dissociative anesthesia, a condition in which pain relief, sedation, and amnesia are
obtained without significant interference with cardiovascular and respiratory systems [142].
At lower, non-dissociative doses (0.1–0.3 mg/kg), ketamine was supposed to be used as an
analgesic in the emergency setting as a single agent or as an adjunct to opioids. Several
clinical trials carried out in adults have confirmed this supposition, despite the fact that
low-dose ketamine was associated with a higher risk of neurological (RR, 2.17; 95% CI,
1.37–3.42; p < 0.001) and psychological events (RR, 13.86; 95% CI, 4.85–39.58; p < 0.001)
compared to opioids [143].
Ketamine is an analgesic and a subdissociative anesthetic. Its potential use in children
was shown in a recent systematic review by Alanazi [144]. This author analyzed the
results of four double-blind, randomized, controlled pediatric trials, in which ketamine
was compared to morphine and fentanyl in children admitted to the emergency foom for
trauma and injuries and treated for acute and severe pain. In two studies, ketamine was
administered intranasally (1 mg/kg and 1.5 mg/kg), in one study by IM (0.2 mg/kg), and
in the last study by IV (0.2 mg/kg). In all the studies, the results showed that ketamine
was non-inferior to opioids in producing pain-reduction outcomes. On the basis of these
findings, the author concluded that ketamine could be considered a suitable alternative to
opioids for the management of acute and severe pain in children [144]. Reports indicated
that ketamine use was accompanied by a more frequent development of adverse events
such as dizziness, sleepiness, an unpleased taste in the mouth, visual disturbances, itchy
nose, sedation, and amnesia [136]. Fortunately, these were mild and transient and did not
impede the treatment duration. However, further studies are needed for a more precise
definition of which route of administration and which dosage to allow to provide an
adequate analgesic effect and obtain the best results with the lowest risk of adverse events.
3.3.3. Dexmedetomidine
Dexmedetomidine is a highly selective α2-adrenoceptor agonist that has been largely
used in adults as an anesthetic, mainly because it provides sedation without causing respira-
tory depression, although it can depress the cardiovascular system [145]. Dexmedetomidine
is an alpha-2-adrenergic receptor agonist that produces analgesia by silencing the central
sympathetic response. In the past it was used in sedation, whereas today it may also be
used as an analgesic adjuvant, reducing the consumption of opioids and their side effects.
Dexmedetomidine has fewer respiratory side effects than opioids, particularly apnea, and
can be administered via a variety of routes including oral, nasal, and IV [145]. This drug
is not approved for use in children. Despite this, the worldwide use of dexmedetomidine
for pediatric anesthesia and analgesia is still increasing [146]. Some studies have mea-
sured its perioperative analgesic effect in children, infants, and neonates, showing that
the intraoperative use of this drug (0.5–1 µg/kg/h) is associated with a reduced postop-
erative opioid administration (RR, 0.31; 95% CI, 0.17–0.59) and decreased pain intensity
(SMD, −1.18; 95% CI, −1.88–−0.48), although no effect upon postoperative nausea and
vomiting could be demonstrated (RR, 0.67; 95% CI, 0.41–1.08) [147]. However, further
studies in children are needed in order to precisely define the most effective and safe drug
dosage for any pediatric age and to obtain official authorization for pediatric use by health
authorities [148,149].
4. Conclusions
Although in recent years, compared to the past, much progress has been made in the
treatment of pain in the context of the pediatric emergency room, there is still a lot of work
to carry out due to the complexity of pediatric patients. Several studies have shown that
very often there is inadequate pain treatment in children, despite the fact that there are
enough tools, both pharmacological and non-pharmacological, available to professionals.
Furthermore, the importance of an adequate treatment of pain in terms of immediate but
also future wellbeing and on the neurodevelopment of the patient has been demonstrated.
Table 1 summarized the main drugs used for pain treatment and their dosage regimes in
pediatric age.
Table 1. Frequently used drugs for pain treatment and their dosage regimes in pediatric age.
Drug Dosage
Paracetamol 10–15 mg/kg,
(acetaminophen) Up to 4 times a day
5–10 mg/kg orally
Ibuprofen 6–8 hourly to a maximum
of 500 mg/day
0.5–1 mg/kg orally
Codeine
6–12 hourly
Calculate exact dose based on the weight of the child
Oral: 0.2–0.4 mg/kg 4–6 hourly; increase if necessary for severe pain
Morphine Intramuscular: 0.1–0.2 mg/kg 4–6 hourly
Intravenous bolus: 0.05–0.1 mg/kg 4–6 hourly (give slowly)
Intravenous infusion: 0.005–0.01 mg/kg/h (in neonates, only 0.002–0.003)
0.04 mg/kg/h–0.15 mg/kg/h i.v./s.c.
Ketamine (titrated to effect: usually maximum 0.3 mg/kg/h–0.6 mg/kg/h)
OR 0.2 mg/kg/dose–0.4 mg/kg/dose orally t.i.d., q.i.d., and p.r.n.
Tramadol 1 mg/kg–2 mg/kg 4–6 hourly (max. of 8 mg/kg/day)
There are international differences regarding the treatment of pain, and in Europe there
are also differences between countries and regions. There is a need to create guidelines
that outline standardized and easy-to-follow pathways for pain recognition and pain
management that are also flexible enough to take into account differences in different
contexts, both in terms of drug availability and the education of staff and also of the
different complexities of patients. It is essential to guarantee an approach to pain that
is as uniform as possible among the pediatric population that prevents oligoanalgesia
and limits the inequalities related to ethnicity and language barriers as much as possible.
In addition, further studies should focus on predictors of the response and incidence of
toxicity for each of therapeutic modality in order to optimally use the different therapeutic
options, especially in emergency settings. Among these predictors, genetic predispositions
to toxicities as well as considering the difficulties in preemptively having this information
in emergency settings should be considered.
Author Contributions: D.C. wrote the first draft of the manuscript; A.R. and M.V. performed the
literature review; N.P. revised the first draft of the manuscript and gave a substantial scientific
contribution; S.E. supervised the project, revised the manuscript and gave a substantial scientific
contribution. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Raja, S.N.; Carr, D.B.; Cohen, M.; Finnerup, N.B.; Flor, H.; Gibson, S.; Keefeh, F.J.; Mogili, J.S.; Ringkampj, M.; Slukak, K.A.; et al.
The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain 2020,
161, 1976–1982. [CrossRef] [PubMed]
2. Williams, A.C.C.; Craig, K.D. Updating the definition of pain. Pain 2016, 157, 2420–2423. [CrossRef] [PubMed]
3. van der Venne, P.; Mürner-Lavanchy, I.; Höper, S.; Koenig, J.; Kaess, M. Physiological response to pain in female adolescents with
nonsuicidal self-injury as a function of severity. J. Affect Disord. 2023, 339, 64–73. [CrossRef] [PubMed]
4. Grout, R.W.; Thompson-Fleming, R.; Carroll, A.E.; Downs, S.M. Prevalence of pain reports in pediatric primary care and
association with demographics, body mass index, and exam findings: A cross-sectional study. BMC Pediatr. 2018, 18, 363.
[CrossRef] [PubMed]
5. GSK Consumer Healthcare Global Pain Index Report 4th Edition—2020. Available online: https://www.gsk.com/media/6351/2
020-global-plain-index-report.pdf (accessed on 20 May 2023).
6. Krauss, B.S.; Calligaris, L.; Green, S.M.; Barbi, E. Current concepts in management of pain in children in the emergency department.
Lancet 2016, 387, 83–92. [CrossRef]
7. Ali, S.; Rajagopal, M.; Stinson, J.; Ma, K.; Vandermeer, B.; Felkar, B.; Schreiner, K.; Proctor, A.; Plume, J.; Hartling, L. Virtual
reality-based distraction for intravenous insertion-related distress in children: A study protocol for a randomised controlled trial.
BMJ Open 2022, 12, e057892. [CrossRef] [PubMed]
8. Young, V.B. Effective Management of Pain and Anxiety for the Pediatric Patient in the Emergency Department. Crit. Care Nurs.
Clin. N. Am. 2017, 29, 205–216. [CrossRef] [PubMed]
9. Haraldstad, K.; Sørum, R.; Eide, H.; Natvig, G.K.; Helseth, S. Pain in children and adolescents: Prevalence, impact on daily life,
and parents’ perception, a school survey. Scand. J. Caring Sci. 2011, 25, 27–36. [CrossRef]
10. Huguet, A.; Miró, J. The severity of chronic pediatric pain: An epidemiological study. J. Pain 2008, 9, 226–236. [CrossRef]
11. Luntamo, T.; Sourander, A.; Santalahti, P.; Aromaa, M.; Helenius, H. Prevalence changes of pain, sleep problems and fatigue
among 8-year-old children: Years 1989, 1999, and 2005. J. Pediatr. Psychol. 2012, 37, 307–318. [CrossRef]
12. Benini, F.; Congedi, S.; Rossin, S.; Pennella, A. The PIPER WEEKEND study. Children’s and adults satisfaction regarding
paediatric pain in Italian Emergency Department. Ann. Ist. Super. Sanita 2018, 54, 12–19. [PubMed]
13. Benini, F.; Piga, S.; Zangardi, T.; Messi, G.; Tomasello, C.; Pirozzi, N.; Cuttini, M.; PIPER Study Group. Nationwide study
of headache pain in Italy shows that pain assessment is still inadequate in paediatric emergency care. Acta Paediatr. 2016,
105, e200–e208. [CrossRef]
14. Gai, N.; Naser, B.; Hanley, J.; Peliowski, A.; Hayes, J.; Aoyama, K. A practical guide to acute pain management in children. J.
Anesth. 2020, 34, 421–433. [CrossRef] [PubMed]
15. Andersson, V.; Bergman, S.; Henoch, I.; Simonsson, H.; Ahlberg, K. Pain and pain management in children and adolescents
receiving hospital care: A cross-sectional study from Sweden. BMC Pediatr. 2022, 22, 252. [CrossRef] [PubMed]
16. World Health Organization. WHO Guidelines on the Management of Chronic Pain in Children Provide Recommended Physical,
Psychological and Pharmacological Interventions for Pain Relief in Children Aged 0–19 Years. Available online: https://www.
who.int/who-revision-of-pain-management-guidelines (accessed on 20 May 2023).
17. British Pain Society Core Standards for Pain Management Services in the U.K. Available online: https://www.britishpainsociety.
org/static/uploads/resources/files/FPM-Core-Standards-2021.pdf (accessed on 20 May 2023).
18. Burlo, F.; Zanon, D.; Minghetti, P.; Taucar, V.; Benericetti, G.; Bennati, G.; Barbi, E.; De Zen, L. Pediatricians’ awareness of galenic
drugs for children with special needs: A regional survey. Ital. J. Pediatr. 2023, 49, 76. [CrossRef] [PubMed]
19. Johnston, C.C.; Stevens, B.J.; Boyer, K.; Porter, F.L. Development of psychologic responses to pain and assessment of pain in
infants and toddlers. In Pain in Infants, Children and Adolescents, 2nd ed.; Schechter, N.L., Berde, C.B., Yaster, M., Eds.; Lippincott
Williams and Wilkins: Philadelphia, PA, USA, 2003; pp. 105–127.
20. Liebelt, E.L. Assessing children’s pain in the emergency department. Clin. Pediatr. Emerg. Med. 2000, 1, 260–269. [CrossRef]
21. Drendel, A.L.; Kelly, B.T.; Ali, S. Pain assessment for children: Overcoming challenges and optimizing care. Pediatr. Emerg. Care
2011, 27, 773–781. [CrossRef]
22. Chiaretti, A.; Pierri, F.; Valentini, P.; Russo, I.; Gargiullo, L.; Riccardi, R. Current practice and recent advances in pediatric pain
management. Eur. Rev. Med. Pharmacol. Sci. 2013, 17 (Suppl. S1), 112–126.
23. Bauman, B.H.; McManus, J.G., Jr. Pediatric pain management in the emergency department. Emerg. Med. Clin. N. Am. 2005,
23, 393–414. [CrossRef]
24. Ali, S.; Drendel, A.L. Responsible and safe use of opioids in children and adolescents in the emergency department. Pediatr.
Emerg. Med. Pract. 2023, 20, 1–24.
25. Manworren, R.C.; Hynan, L.S. Clinical validation of FLACC: Preverbal patient pain scale. Pediatr. Nurs. 2003, 29, 140–146.
[PubMed]
26. Fournier-Charrière, E.; Tourniaire, B.; Carbajal, R.; Cimerman, P.; Lassauge, F.; Ricard, C.; Reiter, F.; Turquin, P.; Lombart, B.;
Letierce, A. EVENDOL, a new behavioral pain scale for children ages 0 to 7 years in the emergency department: Design and
validation. Pain 2012, 153, 1573–1582. [CrossRef] [PubMed]
27. Abou Elella, R.; Adalaty, H.; Koay, Y.N.; Mokrusova, P.; Theresa, M.; Male, B.; Francis, B.; Jarrab, C.; Al Wadai, A. The efficacy of
the COMFORT score and pain management protocol in ventilated pediatric patients following cardiac surgery. Int. J. Pediatr.
Adolesc. Med. 2015, 2, 123–127. [CrossRef]
28. Peters, J.W.; Koot, H.M.; Grunau, R.E.; de Boer, J.; van Druenen, M.J.; Tibboel, D.; Duivenvoorden, H.J. Neonatal Facial Coding
System for assessing postoperative pain in infants: Item reduction is valid and feasible. Clin. J. Pain 2003, 19, e353–e363. [CrossRef]
[PubMed]
29. Crellin, D.J.; Babl, F.E.; Santamaria, N.; Harrison, D. A systematic review of the psychometric properties of the Modified
Behavioral Pain Scale (MBPS). J. Pediatr. Nurs. 2018, 40, 14–26. [CrossRef] [PubMed]
30. Howard, R.F. Current status of pain management in children. JAMA 2003, 290, 2464–2469. [CrossRef] [PubMed]
31. Baeyer, C.L.; Spagrud, L.J.; McCormick, J.C.; Choo, E.; Neville, K.; Connelly, M.A. Three new datasets supporting use of the
Numerical Rating Scale (NRS-11) for children’s self-reports of pain intensity. Pain 2009, 143, 223–227. [CrossRef] [PubMed]
32. Tsze, D.S.; von Baeyer, C.L.; Bulloch, B.; Dayan, P.S. Validation of self-report pain scales in children. Pediatrics 2013, 132, e971–e979.
[CrossRef]
33. Dansie, E.J.; Turk, D.C. Assessment of patients with chronic pain. Br. J. Anaesth. 2013, 111, 19–25. [CrossRef]
34. Goddard, J.M.; Robinson, J.; Hiscock, R. Routine use of the Bath Adolescent Pain Questionnaire in a paediatric pain clinic. Br. J.
Pain 2021, 15, 155–162. [CrossRef]
35. Curtis, S.; Brandow, A.M. Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain
domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease. Hematol. Am.
Soc. Hematol. Educ. Program. 2017, 2017, 542–545. [CrossRef] [PubMed]
36. Fussner, L.M.; Black, W.R.; Lynch-Jordan, A.; Morgan, E.M.; Ting, T.V.; Kashikar-Zuck, S. Utility of the PROMIS Pediatric Pain
Interference Scale in Juvenile Fibromyalgia. J. Pediatr. Psychol. 2019, 44, 436–441. [CrossRef]
37. Lootens, C.C.; Rapoff, M.A. Measures of pediatric pain: 21-numbered circle Visual Analog Scale (VAS), E-Ouch Electronic Pain
Diary, Oucher, Pain Behavior Observation Method, Pediatric Pain Assessment Tool (PPAT), and Pediatric Pain Questionnaire
(PPQ). Arthritis Care Res. 2011, 63 (Suppl. S11), S253–S262. [CrossRef]
38. O’Donnell, F.T.; Rosen, K.R. Pediatric pain management: A review. Mo. Med. 2014, 111, 231–237. [PubMed]
39. Murphy, A.; O’Sullivan, R.; Wakai, A.; Grant, T.S.; Barrett, M.J.; Cronin, J.; Grant, T.S.; Barrett, M.J.; Cronin, J.; McCoy, S.C.; et al.
Intranasal fentanyl for the management of acute pain in children. Cochrane Database Syst. Rev. 2014, 2014, CD009942. [CrossRef]
40. Murphy, A.P.; Hughes, M.; McCoy, S.; Crispino, G.; Wakai, A.; O’Sullivan, R. Intranasal fentanyl for the prehospital management
of acute pain in children. Eur. J. Emerg. Med. 2017, 24, 450–454. [CrossRef] [PubMed]
41. Fowler, M.; Ali, S.; Gouin, S.; Drendel, A.L.; Poonai, N.; Yaskina, M.; Sivakumar, M.; Jun, E.; Dong, K.; Pediatric Emergency
Research Canada. Knowledge, attitudes and practices of Canadian pediatric emergency physicians regarding short-term opioid
use: A descriptive, cross-sectional survey. CMAJ Open 2020, 8, E148–E155. [CrossRef]
42. Marín Gabriel, M.Á.; del Rey Hurtado de Mendoza, B.; Jiménez Figueroa, L.; Medina, V.; Iglesias Fernández, B.; Vázquez
Rodríguez, M.; Escudero Huedo, V.; Medina Malagón, L. Analgesia with breastfeeding in addition to skin-to-skin contact during
heel prick. Arch. Dis. Child. Fetal Neonatal. Ed. 2013, 98, F499–F503. [CrossRef]
43. Shah, P.S.; Herbozo, C.; Aliwalas, L.L.; Shah, V.S. Breastfeeding or breast milk for procedural pain in neonates. Cochrane Database
Syst. Rev. 2012, 12, CD004950. [CrossRef]
44. Ediriweera, Y.; Banks, J.; Hall, L.M.; Heal, C. A study protocol for a randomised controlled trial of ice to reduce the pain of
immunisation: The ICE trial. Aust. J. Gen. Pract. 2022, 51, 173–177. [CrossRef]
45. Lane, E.; Latham, T. Managing pain using heat and cold therapy. Paediatr. Nurs. 2009, 21, 14–18. [CrossRef] [PubMed]
46. Shaefer, J.R.; Lee, S.J.; Anderson, N.K. A Vibration Device to Control Injection Discomfort. Compend. Contin. Educ. Dent. 2017,
38, e5–e8. [PubMed]
47. Mrljak, R.; Arnsteg Danielsson, A.; Hedov, G.; Garmy, P. Effects of Infant Massage: A Systematic Review. Int. J. Environ. Res.
Public. Health 2022, 19, 6378. [CrossRef] [PubMed]
48. Bailey, B.; Trottier, E.D. Managing Pediatric Pain in the Emergency Department. Paediatr. Drugs 2016, 18, 287–301. [CrossRef]
[PubMed]
49. Cozzi, G.; Lucarelli, A.; Borrometi, F.; Corsini, I.; Passone, E.; Pusceddu, S.; Morabito, G.; Barbi, E.; Benini, F. How to recognize
and manage psychosomatic pain in the pediatric emergency department. Ital. J. Pediatr. 2021, 47, 74. [CrossRef] [PubMed]
50. Goldman, R.D.; Behboudi, A. Pilot Randomized Controlled Trial of Virtual Reality vs. Standard-of-Care During Pediatric
Laceration Repair. J. Child. Adolesc. Trauma 2021, 14, 295–298. [CrossRef] [PubMed]
51. Odell, S.; Logan, D.E. Pediatric pain management: The multidisciplinary approach. J. Pain. Res. 2013, 6, 785–790. [CrossRef]
[PubMed]
52. Friedrichsdorf, S.J.; Goubert, L. Pediatric pain treatment and prevention for hospitalized children. Pain Rep. 2019, 5, e804.
[CrossRef]
53. Thompson, T.; Terhune, D.B.; Oram, C.; Sharangparni, J.; Rouf, R.; Solmi, M.; Veronese, N.; Stubbs, B. The effectiveness of
hypnosis for pain relief: A systematic review and meta-analysis of 85 controlled experimental trials. Neurosci. Biobehav. Rev. 2019,
99, 298–310. [CrossRef]
54. Brown, M.L.; Rojas, E.; Gouda, S. A Mind-Body Approach to Pediatric Pain Management. Children 2017, 4, 50. [CrossRef]
55. Ruest, S.; Anderson, A. Management of acute pediatric pain in the emergency department. Curr. Opin. Pediatr. 2016, 28, 298–304.
[CrossRef] [PubMed]
56. Ali, S.; McGrath, T.; Drendel, A.L. An Evidence-Based Approach to Minimizing Acute Procedural Pain in the Emergency
Department and Beyond. Pediatr. Emerg. Care 2016, 32, 36–42. [CrossRef]
57. Prescott, L.F. Paracetamol: Past, present, and future. Am. J. Ther. 2000, 7, 143–147. [CrossRef] [PubMed]
58. Zempsky, W.; Bell, J.; Mossali, V.M.; Kachroo, P.; Siddiqui, K. Common Selfcare Indications of Pain Medications in Children.
Paediatr. Drugs 2023, 25, 321–341. [CrossRef] [PubMed]
59. Graham, G.G.; Scott, K.F. Mechanism of action of paracetamol. Am. J. Ther. 2005, 12, 46–55. [CrossRef] [PubMed]
60. Chiappini, E.; Venturini, E.; Principi, N.; Longhi, R.; Tovo, P.A.; Becherucci, P.; Bonsignori, F.; Esposito, S.; Festini, F.; Galli, L.; et al.
Update of the 2009 Italian Pediatric Society Guidelines about management of fever in children. Clin. Ther. 2012, 34, 1648–1653.e3.
[CrossRef] [PubMed]
61. Ouellet, M.; Percival, M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 2001,
387, 273–280. [CrossRef]
62. Sharma, C.V.; Long, J.H.; Shah, S.; Rahman, J.; Perrett, D.; Ayoub, S.S.; Meht, V. First evidence of the conversion of paracetamol to
AM404 in human cerebrospinal fluid. J. Pain. Res. 2017, 10, 2703–2709. [CrossRef]
63. Mallet, C.; Desmeules, J.; Pegahi, R.; Eschalier, A. An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism
of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact. J. Pain Res. 2023, 16, 1081–1094.
[CrossRef]
64. Baillargeau, C.; Lopez-Cazaux, S.; Charles, H.; Ordureau, A.; DajeanTrutaud, S.; Prud’homme, T.; Hyon, I.; Soueidan, A.;
Alliot-Licht, B.; Renard, E. Post-operative discomforts in children after extraction of primary teeth. Clin. Exp. Dent. Res. 2020,
6, 650–658. [CrossRef]
65. Fux-Noy, A.; Bendahan, Y.; Ungar, E.; Shmueli, A.; Halperson, E.; Ram, D.; Moskovitz, M. Does preoperative paracetamol reduce
pain after dental treatment? A randomized controlled doubleblind study. Quintessence Int. 2020, 51, 732–740. [PubMed]
66. Raslan, N.; Zouzou, T. Comparison of preemptive ibuprofen, acetaminophen, and placebo administration in reducing peri- and
postoperative pain in primary tooth extraction: A randomized clinical trial. Clin. Exp. Dent. Res. 2021, 7, 1045–1052. [CrossRef]
[PubMed]
67. Santos, P.S.; Massignan, C.; de Oliveira, E.V.; Miranda Santana, C.; Bolan, M.; Cardoso, M. Does the pre-emptive administration of
paracetamol or ibuprofen reduce trans- and post-operative pain in primary molar extraction? A randomized placebo-controlled
clinical trial. Int. J. Paediatr. Dent. 2020, 30, 782–790. [CrossRef] [PubMed]
68. Wang, G.; Tan, T.; Liu, Y.; Hong, P. Drugs for acute attack of pediatric migraine: A network meta-analysis of randomized
controlled trials. Clin. Neurol. Neurosurg. 2020, 195, 105853. [CrossRef]
69. Ruperto, N.; Carozzino, L.; Jamone, R.; Freschi, F.; Picollo, G.; Zera, M.; Della Casa Alberighi, O.; Salvatori, E.; Del Vecchio, A.;
Dionisio, P.; et al. A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control
in children with pharyngotonsillitis cared by family pediatricians. Ital. J. Pediatr. 2011, 37, 48. [CrossRef] [PubMed]
70. Mahgoobifard, M.; Mirmesdagh, Y.; Imani, F.; Najaf, A.; Nataj-Majd, M. The analgesic efcacy of preoperative oral Ibuprofen and
acetaminophen in children undergoing adenotonsillectomy: A randomized clinical trial. Anesth. Pain. Med. 2014, 4, e15049.
71. Mirashraf, F.; Tavakolnejad, F.; Amirzargar, B.; Abasi, A.; Amali, A. Efect of paracetamol versus ibuprofen in adenotonsillectomy.
Iran. J. Otorhinolaryngol. 2021, 33, 355–359.
72. Jotić, A.; Savić Vujović, K.; Milovanović, J.; Vujović, A.; Radin, Z.; Milić, N.; Vučković, S.; Medić, B.; Prostran, M. Pain management
after surgical tonsillectomy: Is there a favorable analgesic? Ear Nose Throat J. 2019, 98, 356–361. [CrossRef]
73. Chiappini, E.; Venturini, E.; Remaschi, G.; Principi, N.; Longhi, R.; Tovo, P.A.; Becherucci, P.; Bonsignori, F.; Esposito, S.;
Festini, F.; et al. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J. Pediatr. 2017,
180, 177–183.e1. [CrossRef]
74. Mencía, S.; Alonso, C.; Pallás-Alonso, C.; López-Herce, J. Maternal and Child Health and Development Network Ii Samid Ii.
Evaluation and Treatment of Pain in Fetuses, Neonates and Children. Children 2022, 9, 1688. [CrossRef]
75. Pierce, C.A.; Voss, B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: A meta-analysis and qualitative
review. Ann. Pharmacother. 2010, 44, 489–506. [CrossRef] [PubMed]
76. Clark, E.; Plint, A.C.; Correll, R.; Gaboury, I.; Passi, B. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine
for acute pain relief in children with musculoskeletal trauma. Pediatrics 2007, 119, 460–467. [CrossRef] [PubMed]
77. American Academy of Pediatrics. Acetaminophen toxicity in children. Pediatrics 2001, 108, 1020–1024. [CrossRef] [PubMed]
78. Shivbalan, S.; Sathiyasekeran, M.; Thomas, K. Therapeutic misadventure with paracetamol in children. Ind. J. Pharmacol. 2010,
79. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol.
Rev. 2004, 56, 387–437. [CrossRef] [PubMed]
80. Leroy, S.; Mosca, A.; Landre-Peigne, C.; Cosson, M.A.; Pons, G. Ibuprofen in childhood: Evidence-based review of efficacy and
safety. Arch. Pediatr. 2007, 14, 477–484. [CrossRef] [PubMed]
81. de Martino, M.; Chiarugi, A.; Boner, A.; Montini, G.; de’ Angelis, G.L. Working Towards an Appropriate Use of Ibuprofen in
Children: An Evidence-Based Appraisal. Drugs 2017, 77, 1295–1311. [CrossRef]
82. Tan, E.; Braithwaite, I.; McKinlay, C.; Riley, J.; Hoare, K.; Okesene-Gafa, K.; Semprini, A.; Sheridan, N.; Grant, C.; Johnson, D.; et al.
Randomised controlled trial of paracetamol or ibuprofen, as required for fever and pain in the first year of life, for prevention of
asthma at age 6 years: Paracetamol or ibuprofen in the primary prevention of asthma in Tamariki (PIPPA Tamariki) protocol. BMJ
Open 2020, 10, e038296. [CrossRef]
83. Anderson, B.J.; Hannam, J.A. A target concentration strategy to determine ibuprofen dosing in children. Paediatr. Anaesth. 2019,
29, 1107–1113. [CrossRef]
84. Green, R.; Webb, D.; Jeena, P.M.; Wells, M.; Butt, N.; Hangoma, J.M.; Moodley, R.S.; Maimin, J.; Wibbelink, M.; Mustafa, F.
Management of acute fever in children: Consensus recommendations for community and primary healthcare providers in
sub-Saharan Africa. Afr. J. Emerg. Med. 2021, 11, 283–296. [CrossRef]
85. Hayashi, T.; Kitamura, K.; Hashimoto, S.; Hotomi, M.; Kojima, H.; Kudo, F.; Maruyama, Y.; Sawada, S.; Taiji, H.;
Takahashi, G.; et al. Clinical practice guidelines for the diagnosis and management of acute otitis media in children-2018 update.
Auris Nasus Larynx 2020, 47, 493–526. [CrossRef] [PubMed]
86. Doria, M.; Careddu, D.; Iorio, R.; Verrotti, A.; Chiappini, E.; Barbero, G.M.; Ceschin, F.; Dell’Era, L.; Fabiano, V.; Mencacci, M.; et al.
Paracetamol and ibuprofen in the treatment of fever and acute mild-moderate pain in children: Italian experts’ consensus
statements. Children 2021, 8, 873. [CrossRef] [PubMed]
87. Doniec, Z.; Jackowska, T.; Sybilski, A.; Woroń, J.; Mastalerz-Migas, A. FEVER in children—Recommendations for primary care,
doctors: FEVER COMPASS. Fam. Med. Prim. Care Rev. 2021, 23, 99–115. [CrossRef]
88. Hunter, L.J.; Wood, D.M.; Dargan, P.I. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug
(NSAID) overdose. Open Access Emerg. Med. 2011, 3, 39–48. [CrossRef]
89. Hall, A.H.; Smolinske SCConrad, F.L.; Wruk, K.M.; Kulig KWDwelle, T.L.; Rumack, B.H. Ibuprofen overdose: 126 cases. Ann.
Emerg. Med. 1986, 15, 1308–1313. [CrossRef] [PubMed]
90. Perrott, D.A.; Piira, T.; Goodenough, B.; Champion, G.D. Efficacy and Safety of Acetaminophen vs Ibuprofen for Treating
Children’s Pain or Fever: A Meta-analysis. Arch. Pediatr. Adolesc. Med. 2004, 158, 521–526. [CrossRef] [PubMed]
91. Tan, E.; Braithwaite, I.; McKinlay, C.J.D.; Dalziel, S.R. Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment
of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. JAMA Netw. Open 2020, 3, e2022398.
[CrossRef]
92. Poonai, N.; Bhullar, G.; Lin, K.; Papini, A.; Mainprize, D.; Howard, J.; Teefy, J.; Bale, M.; Langford, C.; Lim, R.; et al. Oral
administration of morphine versus ibuprofen to manage postfracture pain in children: A randomized trial. CMAJ 2014,
186, 1358–1363. [CrossRef]
93. Moss, J.R.; Watcha, M.F.; Bendel, L.P.; McCarthy, D.L.; Witham, S.L.; Glover, C.D. A multicenter, randomized, double-blind
placebo-controlled, single dose trial of the safety and efficacy of intravenous ibuprofen for treatment of pain in pediatric patients
undergoing tonsillectomy. Paediatr. Anaesth. 2014, 24, 483–489. [CrossRef]
94. Smith, C.; Goldman, R.D. Alternating acetaminophen and ibuprofen for pain in children. Can. Fam. Physician 2012, 58, 645–647.
95. Cooney, M.F. Pain Management in Children: NSAID Use in the Perioperative and Emergency Department Settings. Paediatr.
Drugs 2021, 23, 361–372. [CrossRef] [PubMed]
96. Ziesenitz, V.C.; Welzel, T.; van Dyk, M.; Saur, P.; Gorenflo, M.; van den Anker, J.N. Efficacy and Safety of NSAIDs in Infants: A
Comprehensive Review of the Literature of the Past 20 Years. Paediatr. Drugs 2022, 24, 603–655. [CrossRef]
97. Mulita, F.; Karpetas, G.; Liolis, E.; Vailas, M.; Tchabashvili, L.; Maroulis, I. Comparison of analgesic efficacy of acetaminophen
monotherapy versus acetaminophen combinations with either pethidine or parecoxib in patients undergoing laparoscopic
cholecystectomy: A randomized prospective study. Med. Glas. 2021, 18, 27–32.
98. Rutten, K.; Schröder, W.; Christoph, T.; Koch, T.; Tzschentke, T.M. Selectivity profiling of NOP, MOP, DOP and KOP receptor
antagonists in the rat spinal nerve ligation model of mononeuropathic pain. Eur. J. Pharmacol. 2018, 827, 41–48. [CrossRef]
[PubMed]
99. Pathan, H.; Williams, J. Basic opioid pharmacology: An update. Br. J. Pain 2012, 6, 11–16. [CrossRef] [PubMed]
100. Lambert, D.G. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and
mitigation of the misuse crisis. Brit. J. Anaesth. Open 2023, 6, 100141. [CrossRef] [PubMed]
101. Herzig, S.J.; Stefan, M.S.; Pekow, P.S.; Shieh, M.S.; Soares, W.; Raghunathan, K.; Lindenauer, P.K. Risk Factors for Severe Opioid-
Related Adverse Events in a National Cohort of Medical Hospitalizations. J. Gen. Intern. Med. 2020, 35, 538–545. [CrossRef]
[PubMed]
102. Lynn, A.M.; Nespeca, M.K.; Opheim, K.E.; Slattery, J.T. Respiratory effects of intravenous morphine infusions in neonates, infants,
and children after cardiac surgery. Anesth. Analg. 1993, 77, 695–701. [CrossRef]
103. Lynn, A.M.; Nespeca, M.K.; Bratton, S.L.; Shen, D.D. Intravenous morphine in postoperative infants: Intermittent bolus dosing
versus targeted continuous infusions. Pain 2000, 88, 89–95. [CrossRef]
104. Duedahl, T.H.; Hansen, E.H. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr.
Anaesth. 2007, 17, 756–774. [CrossRef]
105. Wong, C.; Lau, E.; Palozzi, L.; Campbell, F. Pain management in children: Part 2—A transition from codeine to morphine for
moderate to severe pain in children. Can. Pharm. J. 2012, 145, 276–279.e1. [CrossRef] [PubMed]
106. Kirchheiner, J.; Henckel, H.B.; Franke, L.; Meineke, I.; Tzvetkov, M.; Uebelhack, R.; Roots, I.; Brockmöller, J. Impact of the
CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genom. 2005,
107. Kirchheiner, J.; Henckel, H.B.; Meineke, I.; Roots, I.; Brockmoller, J. Impact of the CYP2D6 ultrarapid metabolizer genotype on
mirtazapine pharmacokinetics and adverse events in healthy volunteers. J. Clin. Psychopharmacol. 2004, 24, 647–652. [CrossRef]
108. Gasche, Y.; Daali, Y.; Fathi, M.; Chiappe, A.; Cottini, S.; Dayer, P.; Desmeules, J. Codeine intoxication associated with ultrarapid
CYP2D6 metabolism. N. Engl. J. Med. 2004, 351, 2827–2831. [CrossRef] [PubMed]
109. Dean, L.; Kane, M. Codeine Therapy and CYP2D6 Genotype. In Medical Genetics Summaries [Internet]; Pratt, V.M., Scott, S.A.,
Pirmohamed, M., Esquivel, B., Kattman, B.L., Malheiro, A.J., Eds.; National Center for Biotechnology Information (US): Bethesda,
MD, USA, 2012.
110. Aynacioglu, A.S.; Sachse, C.; Bozkurt, A.; Kortunay, S.; Nacak, M.; Schroder, T.; Roots, I.; Brockmöller, J. Low frequency of
defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 1999, 66, 185–192.
[CrossRef] [PubMed]
111. McLellan, R.A.; Oscarson, M.; Seidegard, J.; Evans, D.A.; Ingelman-Sundberg, M. Frequent occurrence of CYP2D6 gene duplication
in Saudi Arabians. Pharmacogenetics 1997, 7, 187–191. [CrossRef] [PubMed]
112. Cartabuke, R.S.; Tobias, J.D.; Taghon, T.; Rice, J. Current practices regarding codeine administration among pediatricians and
pediatric subspecialists. Clin. Pediatr. 2014, 53, 26–30. [CrossRef]
113. Tobias, J.D.; Green, T.P.; Coté, C.J. Section on Anesthesiology and Pain Medicine; Committee on Drugs. Codeine: Time to Say
“No”. Pediatrics 2016, 138, e20162396. [CrossRef]
114. European Medicines Agency Restrictions on Use of Codeine for Pain Relief in Children—CMDh Endorses PRAC Recommendation.
Available online: https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-restrictions-use-codeine-
pain-relief-children-cmdh-endorses-prac_en.pdf (accessed on 20 March 2023).
115. US Food and Drug Administration. FDA Drug Safety Communication: Codeine Use in Certain Children after Tonsillectomy
and/or Adenoidectomy May Lead to Rare, but Life-Threatening Adverse Events or Death in Children Because It Was though
That It Could be Equally Effective with a Lower Risk of Severe Adverse Events. Available online: http://www.fda.gov/Drugs/
DrugSafety/ucm313631.htm (accessed on 20 March 2023).
116. European Medicines Agency. Scientific Conclusions and Grounds for the Variation to the Terms of the Marketing Authorisation(s).
Available online: https://www.ema.europa.eu/en/documents/psusa/tramadol-cmdh-scientific-conclusions-grounds-variation-
amendments-product-information-timetable/00003002/201705_en.pdf (accessed on 20 March 2023).
117. Renny, M.H.; Jent, V.; Townsend, T.; Cerdá, M. Impact of the 2017 FDA Drug Safety Communication on Codeine and Tramadol
Dispensing to Children. Pediatrics 2022, 150, e2021055887. [CrossRef]
118. US Food and Drug Administration. FDA Drug Safety Communication: FDA Restricts Use of Prescription Codeine Pain and
Cough Medicines and Tramadol Pain Medicines in Children; Recommends Against use in Breastfeeding Women. Available
online: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf (accessed on 20 March 2023).
119. Rodieux, F.; Vutskits, L.; Posfay-Barbe, K.M.; Habre, W.; Piguet, V.; Desmeules, J.A.; Samer, C.F. When the Safe Alternative Is Not
That Safe: Tramadol Prescribing in Children. Front. Pharmacol. 2018, 9, 148. [CrossRef]
120. Beakley, B.D.; Kaye, A.M.; Kaye, A.D. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician
2015, 18, 395–400.
121. Lee, C.R.; McTavish, D.; Sorkin, E.M. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties,
and therapeutic potential in acute and chronic pain states. Drugs 1993, 46, 313–340. [CrossRef] [PubMed]
122. Rose, J.B.; Finkel, J.C.; Arquedas-Mohs, A.; Himelstein, B.P.; Schreiner, M.; Medve, R.A. Oral tramadol for the treatment of pain of
7–30 days’ duration in children. Anesth. Analg. 2003, 96, 78–81. [PubMed]
123. Neri, E.; Maestro, A.; Minen, F.; Montico, M.; Ronfani, L.; Zanon, D.; Favret, A.; Messi, G.; Barbi, E. Sublingual ketorolac versus
sublingual tramadol for moderate to severe post-traumatic bone pain in children: A double-blind, randomised, controlled trial.
Arch. Dis. Child. 2013, 98, 721–724. [CrossRef] [PubMed]
124. Uysal, H.Y.; Takmaz, S.A.; Yaman, F.; Baltaci, B.; Başar, H. The efficacy of intravenous paracetamol versus tramadol for
postoperative analgesia after adenotonsillectomy in children. J. Clin. Anesth. 2011, 23, 53–57. [CrossRef] [PubMed]
125. Li, S.; Xiong, H.; Jia, Y.; Li, Z.; Chen, Y.; Zhong, L.; Liu, F.; Qu, S.; Du, Z.; Wang, Y. Oxycodone vs. tramadol in postoperative
parent-controlled intravenous analgesia in children: A prospective, randomized, double-blinded, multiple-center clinical trial.
BMC Anesthesiol. 2023, 23, 152. [CrossRef] [PubMed]
126. Schnabel, A.; Reichl, S.U.; Meyer-Frießem, C.; Zahn, P.K.; Pogatzki-Zahn, E. Tramadol for postoperative pain treatment in children.
Cochrane Database Syst. Rev. 2015, 2015, CD009574. [CrossRef] [PubMed]
127. Borland, M.; Jacobs, I.; King, B.; O’Brien, D. A randomised controlled trial comparing intranasal fentanyl to intravenous morphine
for managing acute pain in the emergency department. Ann. Emerg. Med. 2007, 49, 335–340. [CrossRef]
128. Younge, P.A.; Nicol, M.F.; Kendall, J.M.; Harrington, A.P. A prospective randomised pilot comparison of intranasal fentanyl and
intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg. Med.
1999, 11, 90–94. [CrossRef]
129. Manjushree, R.; Lahiri, A.; Ghosh, B.R.; Laha, A.; Handa, K. Intranasal fentanyl provides adequate postoperative analgesia in
paediatric patients. Can. J. Anaesth. 2002, 49, 190–193.
130. Borland, M.; Jacobs, I.; Geelhoed, G. Intranasal Fentanyl reduces acute pain in children in the emergency department: A safety
and efficacy study. Paediatr. Emergy Med. 2002, 14, 275–280. [CrossRef] [PubMed]
131. Serra, S.; Spampinato, M.D.; Riccardi, A.; Guarino, M.; Pavasini, R.; Fabbri, A.; De Iaco, F. Intranasal Fentanyl for Acute Pain
Management in Children, Adults and Elderly Patients in the Prehospital Emergency Service and in the Emergency Department:
A Systematic Review. J. Clin. Med. 2023, 12, 2609. [CrossRef] [PubMed]
132. European Medicines Agency. Durogesic and Associated Names. Available online: https://www.ema.europa.eu/en/medicines/
human/referrals/durogesic-associated-names (accessed on 20 March 2023).
133. Taylor, K.P.; Singh, K.; Goyal, A. Fentanyl Transdermal. [Updated 2022 Nov 9]. In StatPearls [Internet]; StatPearls Publish-
ing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK555968/ (accessed on 20
March 2023).
134. Armenian, P.; Vo, K.T.; Barr-Walker, J.; Lynch, K.L. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive
review. Neuropharmacology 2018, 134 Pt A, 121–132. [CrossRef]
135. Choi, L.; Ferrell, B.A.; Vasilevskis, E.E.; Pandharipande, P.P.; Heltsley, R.; Ely, E.W.; Stein, C.M.; Girard, T.D. Population
Pharmacokinetics of Fentanyl in the Critically Ill. Crit. Care Med. 2016, 44, 64–72. [CrossRef] [PubMed]
136. Nozari, A.; Akeju, O.; Mirzakhani, H.; Eskandar, E.; Ma, Z.; Hossain, M.A.; Wang, Q.; Greenblatt, D.J.; Martyn, J.A.J. Prolonged
therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. J. Pharm. Pharmacol. 2019,
137. Poonai, N.; Creene, C.; Dobrowlanski, A.; Geda, R.; Hartling, L.; Ali, S.; Bhatt, M.; Trottier, E.D.; Sabhaney, V.; O’Hearn, K.; et al.
Inhaled nitrous oxide for painful procedures in children and youth: A systematic review and meta-analysis. CJEM 2023, Epub
ahead of print. [CrossRef] [PubMed]
138. Heinrich, M.; Menzel, C.; Hoffmann, F.; Berger, M.; von Schweinitz, D. Self-administered procedural analgesia using nitrous
oxide/oxygen (50, 50) in the pediatric surgery emergency room: Effectiveness and limitations. Eur. J. Pediatr. Surg. 2015,
25, 250–256. [PubMed]
139. Zier, J.L.; Liu, M. Safety of high-concentration nitrous oxide by nasal mask for pediatric procedural sedation: Experience with
7802 cases. Pediatr. Emerg. Care 2011, 27, 1107–1112. [CrossRef] [PubMed]
140. Gupta, N.; Gupta, A.; Narayanan MR, V. Current status of nitrous oxide use in pediatric patients. World J. Clin. Pediatr. 2022,
11, 93–104. [CrossRef]
141. Green, S.M.; Roback, M.G.; Kennedy, R.M.; Krauss, B. Clinical practice guideline for emergency department ketamine dissociative
sedation: 2011 update. Ann. Emerg. Med. 2011, 57, 449–461. [CrossRef]
142. Lee, E.N.; Lee, J.H. The Effects of Low-Dose Ketamine on Acute Pain in an Emergency Setting: A Systematic Review and
Meta-Analysis. PLoS ONE 2016, 11, e0165461. [CrossRef] [PubMed]
143. Alanazi, E. The Effectiveness of Ketamine Compared to Opioid Analgesics for management of acute pain in Children in The
Emergency Department: Systematic Review. Am. J. Emerg. Med. 2022, 61, 143–151. [CrossRef] [PubMed]
144. Zhao, Y.; He, J.; Yu, N.; Jia, C.; Wang, S. Mechanisms of Dexmedetomidine in Neuropathic Pain. Front. Neurosci. 2020, 14, 330.
[CrossRef] [PubMed]
145. Mason, K.P.; Lerman, J. Review article: Dexmedetomidine in children: Current knowledge and future applications. Anesth. Analg.
2011, 113, 1129–1142. [CrossRef] [PubMed]
146. Mahmoud, M.; Barbi, E.; Mason, K.P. Dexmedetomidine: What’s New for Pediatrics? A Narrative Review. J. Clin. Med. 2020,
9, 2724. [CrossRef]
147. Sottas, C.E.; Anderson, B.J. Dexmedetomidine: The new all-in-one drug in paediatric anaesthesia? Curr. Opin. Anesthesiol. 2017,
30, 441–451. [CrossRef]
148. Raffaeli, G.; Orenti, A.; Gambino, M.; Peves Rios, W.; Bosis, S.; Bianchini, S.; Tagliabue, C.; Esposito, S. Fever and Pain Management
in Childhood: Healthcare Providers’ and Parents’ Adherence to Current Recommendations. Int. J. Environ. Res. Public Health
2016, 13, 499. [CrossRef]
149. Chiappini, E.; Principi, N.; Longhi, R.; Tovo, P.A.; Becherucci, P.; Bonsignori, F.; Esposito, S.; Festini, F.; Galli, L.; Lucchesi, B.; et al.
Management of fever in children: Summary of the Italian Pediatric Society guidelines. Clin. Ther. 2009, 31, 1826–1843. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.

NFC Cunico 20203 NFC Pain MX in Emergency Room

Uploaded by

Copyright:

Available Formats

NFC Cunico 20203 NFC Pain MX in Emergency Room

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

NFC Cunico 20203 NFC Pain MX in Emergency Room

Uploaded by

Copyright:

Available Formats

pharmaceuticals

Abstract: Pain is a biopsychosocial experience characterized by sensory, physiological, cognitive,

Keywords: ibuprofen; NSAID; opioids; pain; paracetamol

Citation: Cunico, D.; Rossi, A.;

Pharmaceuticals 2023, 16, 1178. https://doi.org/10.3390/ph16081178 https://www.mdpi.com/journal/pharmaceuticals

2. Assessment of Pediatric Pain

3. Treatment of Pediatric Pain

3.1. Non-Pharmacological Approach

3.2. Pharmacological Approach

3.2.3. Non-Steroidal Anti-Inflammatory Drugs

into prostaglandins. Prostaglandin inhibition leads to a strong reduction in inflammation

pethidine and IV acetaminophen and IV parecoxib, respectively) were found to be of

ultra-rapid metabolizers, extensive metabolizers, intermediate metabolizers, and poor

concentrations with an increased risk of opioid-related severe adverse events, including

3.3. Other Analgesic Agents

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.